LTBR acts as a novel immune checkpoint of tumor-associated macrophages for lung adenocarcinoma immunotherapy
2023
- 79Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage79
- Views62
- Downloads17
Dataset Description
Background: Tumor-associated macrophages (TAMs) has been reported to mediate the resistance of LUAD patients to ICI therapy. However, its underlying mechanisms and whether TAMs could be promising targets to overcome the non-response after ICI application remain to be unveiled. Methods: Immune multi-omics analysis was implemented with a large clinical cohort encompassing 1045 LUAD cases to screen out potential immune checkpoints. scRNA-seq analysis revealed their distribution in LUAD immune cells. The key molecule and related mechanisms were investigated in vitro and in vivo. Clinical verification in ICI therapy cohorts and TAMs-targeted delivery system had been performed for further clinical translation. Findings: LTBR, as a potential immune checkpoint, was screened out. Its high expression, duplication and low methylation were corelated with LUAD unfavorable survival. scRNA-seq and FACS analysis showed the highest expression of LTBR in TAMs. Moreover, TAM-targeted inhibition of LTΒ...
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know